SPANX family member N3Genealiases: CT11.8 · SPANX-N3
Q-omics provides the consensus-scored SPANXN3 profile across patient tissues and cancer cell-line models. SPANXN3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SPANXN3 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, SPANXN3 RNA expression shows 4,630 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, and STAD as cancer lineages where SPANXN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPANXN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPANXN3 survival associations across molecular data types. SPANXN3 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPANXN3 RNA expression–survival associations across cancer types. High SPANXN3 expression shows unfavorable associations in HNSC, UVM, KICH, CESC, LUSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SPANXN3 RNA expression.
This table summarizes SPANXN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPANXN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPANXN3 shows higher tumor expression in HNSC, BRCA and KIRP. The HNSC box plot shows higher SPANXN3 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p = .008).
This table shows molecular features associated with SPANXN3 in patient tissues and cancer cell lines. In patient samples, SPANXN3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPANXN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
